
|Videos|November 16, 2017
Dr. Ledermann on Rucaparib Maintenance in Ovarian Cancer
Author(s)Jonathan Ledermann, MD
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses rucaparib (Rubraca) maintenance in ovarian cancer.
Advertisement
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses rucaparib (Rubraca) maintenance in ovarian cancer.
The ARIEL3 trial is currently looking at maintenance therapy with rucaparib by giving patients chemotherapy, and then maintaining the response and freedom from progression by using a PARP inhibitor. Rucaparib is licensed in the United States for the treatment of BRCA-mutated ovarian cancer.
ARIEL3 is the third randomized trial in this setting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































